Fuji Keizai, a leader in bio-related market assessments, sees a growing wellness market in Japan, among which are 1,4 billion for rare sugars such as psicose, and 5,7 billion yen for acai palm supplements.
Nikkei Biotech news release, July 11, 2014
Fuji Keizai, a leader in bio-related market assessments, sees a growing wellness market in Japan, among which are 1,4 billion for rare sugars such as psicose, and 5,7 billion yen for acai palm supplements.
Nikkei Biotech news release, July 11, 2014
This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.
Accept or Deny